Generic Sweden Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Generic Sweden wird ein jährliches Gewinn- und Umsatzwachstum von 19.8% bzw. 12.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 19.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 53.5% betragen.

Wichtige Informationen

19.8%

Wachstumsrate der Gewinne

19.8%

EPS-Wachstumsrate

IT Gewinnwachstum17.2%
Wachstumsrate der Einnahmen12.7%
Zukünftige Eigenkapitalrendite53.5%
Analystenabdeckung

Low

Zuletzt aktualisiert15 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Generic Sweden's (STO:GENI) Profits May Not Reveal Underlying Issues

Aug 29
Generic Sweden's (STO:GENI) Profits May Not Reveal Underlying Issues

Some Confidence Is Lacking In Generic Sweden AB (STO:GENI) As Shares Slide 29%

Feb 25
Some Confidence Is Lacking In Generic Sweden AB (STO:GENI) As Shares Slide 29%

Generic Sweden's (STO:GENI) Solid Earnings May Rest On Weak Foundations

Feb 22
Generic Sweden's (STO:GENI) Solid Earnings May Rest On Weak Foundations

Do Generic Sweden's (STO:GENI) Earnings Warrant Your Attention?

Feb 19
Do Generic Sweden's (STO:GENI) Earnings Warrant Your Attention?

Should You Investigate Generic Sweden AB (STO:GENI) At kr60.20?

Jan 11
Should You Investigate Generic Sweden AB (STO:GENI) At kr60.20?

Is Now The Time To Look At Buying Generic Sweden AB (STO:GENI)?

Sep 16
Is Now The Time To Look At Buying Generic Sweden AB (STO:GENI)?

Should You Be Adding Generic Sweden (STO:GENI) To Your Watchlist Today?

Jul 01
Should You Be Adding Generic Sweden (STO:GENI) To Your Watchlist Today?

Is Generic Sweden AB (STO:GENI) Potentially Undervalued?

Feb 18
Is Generic Sweden AB (STO:GENI) Potentially Undervalued?

We Ran A Stock Scan For Earnings Growth And Generic Sweden (STO:GENI) Passed With Ease

Aug 26
We Ran A Stock Scan For Earnings Growth And Generic Sweden (STO:GENI) Passed With Ease

A Look At The Intrinsic Value Of Generic Sweden AB (STO:GENI)

Apr 28
A Look At The Intrinsic Value Of Generic Sweden AB (STO:GENI)

Is It Time To Consider Buying Generic Sweden AB (STO:GENI)?

Apr 08
Is It Time To Consider Buying Generic Sweden AB (STO:GENI)?

Is Now The Time To Put Generic Sweden (STO:GENI) On Your Watchlist?

Feb 18
Is Now The Time To Put Generic Sweden (STO:GENI) On Your Watchlist?

Calculating The Fair Value Of Generic Sweden AB (STO:GENI)

Jan 10
Calculating The Fair Value Of Generic Sweden AB (STO:GENI)

With EPS Growth And More, Generic Sweden (STO:GENI) Is Interesting

Nov 08
With EPS Growth And More, Generic Sweden (STO:GENI) Is Interesting

Here's Why I Think Generic Sweden (STO:GENI) Is An Interesting Stock

Jul 17
Here's Why I Think Generic Sweden (STO:GENI) Is An Interesting Stock

Here's Why I Think Generic Sweden (STO:GENI) Might Deserve Your Attention Today

Apr 13
Here's Why I Think Generic Sweden (STO:GENI) Might Deserve Your Attention Today

Is Generic Sweden AB (STO:GENI) A Smart Pick For Income Investors?

Mar 26
Is Generic Sweden AB (STO:GENI) A Smart Pick For Income Investors?

A Look At The Intrinsic Value Of Generic Sweden AB (STO:GENI)

Mar 04
A Look At The Intrinsic Value Of Generic Sweden AB (STO:GENI)

Should You Take Comfort From Insider Transactions At Generic Sweden AB (STO:GENI)?

Feb 14
Should You Take Comfort From Insider Transactions At Generic Sweden AB (STO:GENI)?

Will Weakness in Generic Sweden AB's (STO:GENI) Stock Prove Temporary Given Strong Fundamentals?

Jan 26
Will Weakness in Generic Sweden AB's (STO:GENI) Stock Prove Temporary Given Strong Fundamentals?

Here's Why I Think Generic Sweden (STO:GENI) Might Deserve Your Attention Today

Jan 05
Here's Why I Think Generic Sweden (STO:GENI) Might Deserve Your Attention Today

Is There More To The Story Than Generic Sweden's (STO:GENI) Earnings Growth?

Dec 16
Is There More To The Story Than Generic Sweden's (STO:GENI) Earnings Growth?

Does Generic Sweden AB (STO:GENI) Have A Place In Your Dividend Portfolio?

Nov 25
Does Generic Sweden AB (STO:GENI) Have A Place In Your Dividend Portfolio?

Gewinn- und Umsatzwachstumsprognosen

OM:GENI - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20262233734351
12/31/20252033229301
12/31/20241772625261
9/30/2024168242126N/A
6/30/2024159231718N/A
3/31/2024151233133N/A
12/31/2023143232022N/A
9/30/2023139241822N/A
6/30/2023134231923N/A
3/31/202313121913N/A
12/31/2022128201417N/A
9/30/2022124191617N/A
6/30/2022121181718N/A
3/31/2022120191819N/A
12/31/2021115181820N/A
9/30/2021107171617N/A
6/30/2021100151516N/A
3/31/202190131415N/A
12/31/202082111213N/A
9/30/202078101011N/A
6/30/2020751089N/A
3/31/202072978N/A
12/31/201970989N/A
9/30/2019689910N/A
6/30/20196471011N/A
3/31/20196271213N/A
12/31/20186061112N/A
9/30/201859657N/A
6/30/2018576N/A5N/A
3/31/2018555N/A0N/A
12/31/2017534N/A1N/A
9/30/2017512N/A0N/A
6/30/2017512N/A2N/A
3/31/2017513N/A5N/A
12/31/2016513N/A6N/A
9/30/2016674N/A8N/A
6/30/2016784N/A7N/A
3/31/2016945N/A7N/A
12/31/20151105N/A8N/A
9/30/20151114N/A9N/A
6/30/20151135N/A9N/A
3/31/20151114N/A7N/A
12/31/20141102N/A4N/A
9/30/2014106-11N/A5N/A
6/30/2014105-11N/A5N/A
3/31/2014108-10N/A4N/A
12/31/2013116-9N/A9N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: GENIDas prognostizierte Gewinnwachstum (19.8% pro Jahr) liegt über der Sparquote (1.2%).

Ertrag vs. Markt: GENIDie Erträge des Unternehmens (19.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (15% pro Jahr).

Hohe Wachstumserträge: GENIDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: GENIDie Einnahmen des Unternehmens (12.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (-0% pro Jahr).

Hohe Wachstumseinnahmen: GENIDie Einnahmen des Unternehmens (12.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.


Wachstumsprognosen für den Gewinn je Aktie


Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: GENIDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich sehr hoch sein (53.5%).


Wachstumsunternehmen entdecken